Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 12

1.

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S.

N Engl J Med. 2012 Oct 25;367(17):1596-606. doi: 10.1056/NEJMoa1207756.

2.

Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.

Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT.

Oncogene. 2014 Jun 5;33(23):2949-55. doi: 10.1038/onc.2013.244. Epub 2013 Jun 24. Review.

3.

Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis.

Li P, Wu H, Zhang H, Shi Y, Xu J, Ye Y, Xia D, Yang J, Cai J, Wu Y.

Gut. 2015 Sep;64(9):1419-25. doi: 10.1136/gutjnl-2014-308260. Epub 2014 Sep 19. Review.

PMID:
25239119
4.

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.

Mao C, Yang ZY, Hu XF, Chen Q, Tang JL.

Ann Oncol. 2012 Jun;23(6):1518-25. doi: 10.1093/annonc/mdr464. Epub 2011 Oct 29. Review.

5.

Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.

Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, Ding H, Mao C, Tang JL.

Int J Cancer. 2013 Oct 15;133(8):1914-25. doi: 10.1002/ijc.28153. Epub 2013 Jul 13. Review. Erratum in: Int J Cancer. 2014 Jul 15;135(2):E2.

6.

Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review.

Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S.

J Pathol. 2010 Dec;222(4):350-66. doi: 10.1002/path.2774. Review.

7.

Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review.

Shima K, Nosho K, Baba Y, Cantor M, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S.

Int J Cancer. 2011 Mar 1;128(5):1080-94. doi: 10.1002/ijc.25432. Review.

8.

Gene of the month: PIK3CA.

Lai K, Killingsworth MC, Lee CS.

J Clin Pathol. 2015 Apr;68(4):253-7. doi: 10.1136/jclinpath-2015-202885. Epub 2015 Feb 16. Review.

PMID:
25688137
9.

Aspirin and colorectal cancer: back to the future.

Tougeron D, Sha D, Manthravadi S, Sinicrope FA.

Clin Cancer Res. 2014 Mar 1;20(5):1087-94. doi: 10.1158/1078-0432.CCR-13-2563. Epub 2013 Dec 10. Review.

10.

Oncogenic mutations of PIK3CA in human cancers.

Samuels Y, Waldman T.

Curr Top Microbiol Immunol. 2010;347:21-41. doi: 10.1007/82_2010_68. Review.

11.

Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?

Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MK, Venning G.

Br J Cancer. 2011 Oct 11;105(8):1107-13. doi: 10.1038/bjc.2011.289. Epub 2011 Aug 16. Review.

12.

PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.

Keppler-Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC, Alomari A, Ezaki M, Dobyns W, Biesecker LG.

Am J Med Genet A. 2015 Feb;167A(2):287-95. doi: 10.1002/ajmg.a.36836. Epub 2014 Dec 31.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk